All articles tagged with #non responders
GLP-1 weight‑loss drugs such as Wegovy and Zepbound help many people lose weight, but about 10% are non-responders who shed little to no weight. Researchers are investigating genetics, hormones, and timing to predict response, and some doctors use genetic tests to guide therapy. For non-responders, options include switching medications or bariatric surgery, and new drugs targeting other hormones are in development.
Millions of Americans using weight-loss drugs like Ozempic are experiencing unexpected results, with about 20% not losing significant weight and some even gaining weight. Experts attribute this to individual biological differences, underlying health conditions, and the complex nature of obesity. Despite the high cost and potential side effects, the Biden administration plans to expand Medicare and Medicaid coverage for these drugs. However, skepticism remains due to the variability in effectiveness and potential for weight regain after discontinuation.
Semaglutide (Ozempic/Wegovy), a medication approved for weight loss, does not work for all patients. Some patients do not respond to the drug, while others experience severe side effects that force them to stop taking it. The reasons for non-response are unclear, but it may be related to underlying health conditions or metabolic derangements. Genetic factors, endocrine disorders, and medication interactions need further research to better understand treatment options. Gastrointestinal side effects, such as nausea, vomiting, and diarrhea, are common with semaglutide and can be severe for some patients. Insurance coverage and biases against using medication therapy for obesity can also pose challenges in managing poor reactions. Physicians may consider alternative treatments for patients who do not respond to semaglutide.